|
New whitepaper on Selvita Protein Modeling Platform |
|
Tuesday, 21 October 2008 |
Thanks to international effort of genome sequencing projects, last years brought massive amount of new amino acid sequences. Although experimental methods for determining protein structure are providing new structures, they cannot keep the pace at which sequences are resolved. For a large fraction of proteins whose structures will not be determined experimentally, computational methods can provide valuable information.
Protein modeling in silico is a strong competency at Selvita. Our development team has extensive experience in protein modeling, structure prediction and mining of protein structure and sequence data on genomic scale. The full scope and high interoperability of our protein modeling tools makes Selvita unique among collaboration partners in the field.
We have implemented an unique protein modeling technology. Our innovative, comparative modeling strategies enable determination of high quality structures as well as protein fold recognition in more difficult cases, when standard sequence search methods have failed.
Detailed information on Selvita Protein Modeling Platform is included in the whitepaper:
Selvita Protein Modeling Platform
|
|
|
Innovative compound with hypotensive activity available for partnering |
|
Tuesday, 21 October 2008 |
SEL92 is a novel, patented new chemical entity presenting hypotensive activity. SEL92 has been shown safe, not showing neither neurotoxicity or cardiotoxicity, when tested in vivo. It has a well-defined mechanism of action and good specificity as observed in functional ex-vivo and in vivo assays.
SEL92 can be further developed in the field of hypertensive disorders including pregnancy-induced hypertension (pre-eclampsia), pulmonary hypertension as well as renovascular hypertension.
SEL92 is currently developed by Selvita and available for partnering.
If you are interested in this opportunity please contact
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
.
|
|
|
Selvita appoints Dr Nicolas D. Beuzen as Chief Scientific Officer and Member of the Management Board |
|
Sunday, 11 May 2008 |
Selvita Sp. z o.o. , a drug discovery company headquartered in Krakow, Poland, announced today the appointment of Dr. Nicolas D. Beuzen as its Chief Scientific Officer and Member of the Management Board. Dr. Beuzen will oversee all Selvita’s drug research projects.
"Nicolas is a remarkable addition to our management team," stated Pawel Przewiezlikowski, Chief Executive Officer of Selvita. "His scientific and business education, as well as his experience with a big pharmaceutical company, a start-up and in outsourced drug development will provide an invaluable perspective for our future growth”. |
|
Read more...
|
|
|
Read-Gene and Selvita launch a strategic partnership in the area of genetic background of cancer development and its treatments |
|
Monday, 31 March 2008 |
|
Read-Gene headquartered in Szczecin, Poland and Selvita, headquartered in Krakow, Poland announced today a strategic research, development and marketing partnership in the area of genetic background of neoplasm development and related treatments. The goal of the cooperation is to take advantage of the best of scientific, technical and business competencies of both companies in order to develop novel oncology diagnostics and treatment solutions. The foundation of the partnership is laid on twenty years of research of Read-Gene team into the genetic background of neoplasm development and its latest research on genomic-based targeting of cancer therapies. Selvita will contribute to the partnership scientific resources, bioinformatics tools and its expertise in the pharmaceutical market. |
|
Read more...
|
|
|
Selvita becomes the strategic investor in BioCentrum |
|
Wednesday, 26 March 2008 |
|
Selvita and BioCentrum - both product and solution providers to the pharmaceutical and biotechnology industry have entered into a strategic cooperation agreement. As part of the agreement BioCentrum will become a part of Selvita group and will concentrate the potential of both companies in the area of ADMET contract research, including microbiology and biochemistry assays and the development and production of proteins. Selvita will continue to develop its innovative compound pipeline as well as offer advanced services to the drug industry including drug discovery and design, bioinformatics and chemical informatics. |
|
Read more...
|
|
|
|
